Moderna’s mRNA-1083, or mCOMBRIAX, has been given the green light in Europe, marking it as the world's first authorized combination shot for influenza and COVID-19. The decision, following a positive review from the European Medicines Agency (EMA) back in February, paves the way for this innovative vaccine.

Moderna CEO Stéphane Bancel welcomed the news, stating: 'By combining protection against two significant respiratory viruses in a single dose, our vaccine aims to simplify immunization for adults, particularly those at high risk.' The mCOMBRIAX is designed to offer an important new option for Europeans while also aiming to strengthen the resilience of healthcare systems across Europe.

The combination shot combines Moderna’s COVID-19 vaccine with an investigational influenza vaccine called mRNA-1010. Findings from a Phase III clinical trial involving around 4,000 adults showed that mCOMBRIAX spurred statistically significant higher immune responses against common flu strains and SARS-CoV-2 than the comparator vaccines.

While Europe moves forward with this groundbreaking combination vaccine, it remains to be seen when or if the US will follow suit. The decision could have far-reaching implications for global pandemic preparedness and vaccination strategies in the coming years.